Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy-Reference-Cited by-同舟云学术

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy

Published:2015-07-25 Issue:2 Volume:24 Page:871-878
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Ando Yosuke,Hayashi Takahiro,Ito Kaori,Suzuki Eri,Mine Naoyuki,Miyamoto Ayumi,Oya Miyuki,Matsuda Hidezo,Isaji Ami,Nakanishi Toru,Imaizumi Kazuyoshi,Shibata Tomoyuki,Okada Tatsuyoshi,Sakurai Kazuo,Naito Kensei,Uyama Ichiro,Kawada Kenji,Takahashi Hiroshi,Yamada Shigeki

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-015-2856-9.pdf

Reference33 articles.

1. Bonadonna G, Valagussa P, Moliterni A et al (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 332:901–906

2. Epelbaum R, Faraggi D, Ben-Arie Y et al (1990) Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66:1124–1129

3. Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491–497

4. Alexandre J, Gross-Goupil M, Falissard B et al (2003) Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 14:36–41

5. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:S232–S243

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy;Expert Opinion on Pharmacotherapy;2023-11-27

2. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis;Supportive Care in Cancer;2023-08

3. The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review;Advances in Clinical and Experimental Medicine;2023-04-07

4. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-11-16

5. Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Conditions: A Case Series;Journal of Pain and Symptom Management;2021-09